Bradley Foster & Sargent Inc. CT Sells 223,860 Shares of Abbott Laboratories $ABT

Bradley Foster & Sargent Inc. CT cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 26.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 611,016 shares of the healthcare product maker’s stock after selling 223,860 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Abbott Laboratories were worth $62,733,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares during the period. United Bank boosted its holdings in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC increased its position in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after purchasing an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board increased its position in Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABT has been the topic of a number of recent analyst reports. The Goldman Sachs Group dropped their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. Barclays dropped their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Finally, Mizuho decreased their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Insider Activity

In related news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $103.13 on Friday. The stock has a market capitalization of $179.63 billion, a price-to-earnings ratio of 33.38, a PEG ratio of 2.00 and a beta of 0.61. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock’s 50 day moving average price is $91.61 and its two-hundred day moving average price is $101.33.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.